Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 12/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.41 |
| ▸ | GSK3B | P49841 | 5/20 | 0.40 |
| ▸ | CDK1 | P06493 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | CDK9 | P50750 | 2/20 | 0.39 |
| ▸ | CDK3 | Q00526 | 2/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22659710 | 1.00 | BTK (0.53) | BTKLCKMAPK14GSK3BCDK1 | |
| SCHEMBL29533081 | 0.94 | BTK (0.53) | BTKLCKMAPK14GSK3BCDK1 | |
| SCHEMBL22659452 | 0.94 | BTK (0.53) | BTKLCKMAPK14GSK3BCDK1 | |
| SCHEMBL22660078 | 0.92 | BTK (0.52) | BTKLCKMAPK14GSK3BCDK1 | |
| SCHEMBL29533277 | 0.92 | BTK (0.52) | BTKLCKMAPK14GSK3BCDK1 | |
| SCHEMBL22659653 | 0.91 | BTK (0.52) | BTKLCKMAPK14GSK3BCDK1 | |
| SCHEMBL29533542 | 0.91 | BTK (0.52) | BTKLCKMAPK14GSK3BCDK1 | |
| SCHEMBL22659773 | 0.91 | BTK (0.55) | BTKLCKMAPK14GSK3BCDK1 | |
| SCHEMBL29533566 | 0.91 | BTK (0.55) | BTKLCKMAPK14GSK3BCDK1 | |
| SCHEMBL22659928 | 0.90 | BTK (0.54) | BTKLCKMAPK14GSK3BCDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240838-B2 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-20220259194-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2022-08-18 | — | — | US | disclosed |
| EP-3969124-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240838-B2 | Inhibiting agents for Bruton's tyrosine kinase | ABL1, BTK, LYN | BTK 2/4885LCK 8/4885MAPK14 266/4885 |
| US-20220259194-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | BTK 2/4885LCK 8/4885MAPK14 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.